首页> 美国卫生研究院文献>Elsevier Sponsored Documents >Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy
【2h】

Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy

机译:使用基于碳纳米管的疫苗递送系统双重刺激抗原呈递细胞用于癌症免疫治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Although anti−cancer immuno−based combinatorial therapeutic approaches have shown promising results, efficient tumour eradication demands further intensification of anti−tumour immune response. With the emerging field of nanovaccinology, multi−walled carbon nanotubes (MWNTs) have manifested prominent potentials as tumour antigen nanocarriers. Nevertheless, the utilization of MWNTs in co−delivering antigen along with different types of immunoadjuvants to antigen presenting cells (APCs) has not been investigated yet. We hypothesized that harnessing MWNT for concurrent delivery of cytosine−phosphate−guanine oligodeoxynucleotide (CpG) and anti-CD40 Ig (αCD40), as immunoadjuvants, along with the model antigen ovalbumin (OVA) could potentiate immune response induced against OVA−expressing tumour cells. We initially investigated the effective method to co−deliver OVA and CpG using MWNT to the APC. Covalent conjugation of OVA and CpG prior to loading onto MWNTs markedly augmented the CpG−mediated adjuvanticity, as demonstrated by the significantly increased OVA−specific T cell responses in vitro and in C57BL/6 mice. αCD40 was then included as a second immunoadjuvant to further intensify the immune response. Immune response elicited in vitro and in vivo by OVA, CpG and αCD40 was significantly potentiated by their co−incorporation onto the MWNTs. Furthermore, MWNT remarkably improved the ability of co−loaded OVA, CpG and αCD40 in inhibiting the growth of OVA−expressing B16F10 melanoma cells in subcutaneous or lung pseudo−metastatic tumour models. Therefore, this study suggests that the utilization of MWNTs for the co−delivery of tumour−derived antigen, CpG and αCD40 could be a competent approach for efficient tumours eradication.
机译:尽管基于抗癌免疫的组合治疗方法已显示出令人鼓舞的结果,但有效的根除肿瘤需要进一步增强抗肿瘤免疫反应。随着纳米疫苗学的兴起,多壁碳纳米管(MWNTs)作为肿瘤抗原纳米载体已显示出巨大的潜力。然而,尚未对在共同递送抗原中使用MWNT以及将不同类型的免疫佐剂用于抗原呈递细胞(APC)进行研究。我们假设利用MWNT同时递送胞嘧啶-磷酸-鸟嘌呤寡脱氧核苷酸(CpG)和抗CD40 Ig(αCD40)作为免疫佐剂,以及模型抗原卵清蛋白(OVA)可以增强针对表达OVA的肿瘤细胞诱导的免疫应答。我们最初研究了使用MWNT向APC共传送OVA和CpG的有效方法。加载到MWNT上之前,OVA和CpG的共价偶联显着增强了CpG介导的佐剂作用,这在体外和C57BL / 6小鼠中均显着增加了OVA特异性T细胞反应。然后包括αCD40作为第二种免疫佐剂,以进一步增强免疫应答。 OVA,CpG和αCD40在体外和体内引起的免疫反应通过将它们共掺入MWNT而显着增强。此外,在皮下或肺假转移肿瘤模型中,MWNT显着提高了共同加载的OVA,CpG和αCD40抑制表达OVA的B16F10黑色素瘤细胞生长的能力。因此,这项研究表明利用MWNTs共同递送肿瘤衍生抗原,CpG和αCD40可能是有效根除肿瘤的有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号